The authors review the current regulatory framework for the selection of drug substance starting materials. The term starting material has been adopted to indicate the point where regulatory change ...
The author describes how providing appropriate information about the API in the Common Technical Document can aid FDA's review of an abbreviated new drug application. The generic drug market has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results